|
15
|
105
|
8vyfL |
Sars-cov-2 s ntd (c.37 lambda variant) plus s2l20 and s2x303 fabs, local refinement |
|
27
|
121
|
8vyfB |
Sars-cov-2 s ntd (c.37 lambda variant) plus s2l20 and s2x303 fabs, local refinement |
|
44
|
285
|
8vyfA |
Sars-cov-2 s ntd (c.37 lambda variant) plus s2l20 and s2x303 fabs, local refinement |
|
14
|
119
|
8vyfH |
Sars-cov-2 s ntd (c.37 lambda variant) plus s2l20 and s2x303 fabs, local refinement |
|
16
|
126
|
8vyeA |
Sars-cov-2 s (c.37 lambda variant) plus s309, s2l20, and s2x303 fabs |
|
15
|
121
|
8vyeB |
Sars-cov-2 s (c.37 lambda variant) plus s309, s2l20, and s2x303 fabs |
|
25
|
105
|
8vyfC |
Sars-cov-2 s ntd (c.37 lambda variant) plus s2l20 and s2x303 fabs, local refinement |
|
15
|
106
|
8vyeD |
Sars-cov-2 s (c.37 lambda variant) plus s309, s2l20, and s2x303 fabs |
|
16
|
105
|
8vyeL |
Sars-cov-2 s (c.37 lambda variant) plus s309, s2l20, and s2x303 fabs |
|
232
|
1133
|
8gdrA |
Sars-cov2 s protein structure in complex with neutralizing monoclonal antibody 002-s21b10 |
|
36
|
224
|
8gdrC |
Sars-cov2 s protein structure in complex with neutralizing monoclonal antibody 002-s21b10 |
|
33
|
216
|
8gdrD |
Sars-cov2 s protein structure in complex with neutralizing monoclonal antibody 002-s21b10 |
|
263
|
1207
|
8ifnB |
Mers-cov spike trimer in complex with nanobody vhh-t148 |
|
190
|
596
|
8wgwB |
Local refinement of rbd-ace2 |
|
145
|
596
|
8wgvD |
Ba.2(s375) spike (s6p)/hace2 complex |
|
191
|
1123
|
8wgvA |
Ba.2(s375) spike (s6p)/hace2 complex |
|
35
|
198
|
8wgwA |
Local refinement of rbd-ace2 |
|
24
|
128
|
8ifnA |
Mers-cov spike trimer in complex with nanobody vhh-t148 |
|
207
|
1134
|
8g77A |
Sars-cov-2 spike/nb6 complex |
|
226
|
1134
|
8g71A |
Spike/nb2 complex with 1 rbd up |
|
206
|
1134
|
8g76A |
Sars-cov-2 spike/nb5 complex |
|
200
|
1134
|
8g70A |
Sars-cov-2 spike/nanobody mixture complex |
|
229
|
1123
|
8cinA |
Ba.4/5-5 fab in complex with sars-cov-2 ba.4 spike glycoprotein |
|
17
|
118
|
8g78E |
Local refinement of sars-cov-2 spike/nanobody mixture complex around ntd |
|
23
|
127
|
8g7cE |
Local refinement of sars-cov-2 spike/nb4 complex with 2 rbds up and 3 nb4 bound |
|
46
|
214
|
8cinF |
Ba.4/5-5 fab in complex with sars-cov-2 ba.4 spike glycoprotein |
|
38
|
223
|
8cinE |
Ba.4/5-5 fab in complex with sars-cov-2 ba.4 spike glycoprotein |
|
22
|
127
|
8g70N |
Sars-cov-2 spike/nanobody mixture complex |
|
12
|
118
|
8g70F |
Sars-cov-2 spike/nanobody mixture complex |
|
16
|
115
|
8g79M |
Local refinement of sars-cov-2 spike/nanobody mixture complex around rbd |
|
80
|
607
|
8g7cA |
Local refinement of sars-cov-2 spike/nb4 complex with 2 rbds up and 3 nb4 bound |
|
18
|
114
|
8g70E |
Sars-cov-2 spike/nanobody mixture complex |
|
29
|
199
|
8g79A |
Local refinement of sars-cov-2 spike/nanobody mixture complex around rbd |
|
20
|
113
|
8g78H |
Local refinement of sars-cov-2 spike/nanobody mixture complex around ntd |
|
18
|
118
|
8g77F |
Sars-cov-2 spike/nb6 complex |
|
19
|
114
|
8g76E |
Sars-cov-2 spike/nb5 complex |
|
14
|
115
|
8g70M |
Sars-cov-2 spike/nanobody mixture complex |
|
65
|
686
|
8g78A |
Local refinement of sars-cov-2 spike/nanobody mixture complex around ntd |
|
26
|
127
|
8g79N |
Local refinement of sars-cov-2 spike/nanobody mixture complex around rbd |
|
236
|
1130
|
8vklA |
Cryo-em structure of sars-cov-2 xbb.1.5 spike protein in complex with mouse ace2 (conformation 2) |
|
234
|
1130
|
8vkmA |
Cryo-em structure of sars-cov-2 xbb.1.5 spike protein in complex with mouse ace2 (conformation 1) |
|
235
|
1130
|
8vkoA |
Cryo-em structure of sars-cov-2 xbb.1.5 spike protein in complex with human ace2 |
|
204
|
593
|
8vklD |
Cryo-em structure of sars-cov-2 xbb.1.5 spike protein in complex with mouse ace2 (conformation 2) |
|
210
|
1130
|
8vkkA |
Cryo-em structure of sars-cov-2 xbb.1.5 spike protein |
|
201
|
593
|
8vkmD |
Cryo-em structure of sars-cov-2 xbb.1.5 spike protein in complex with mouse ace2 (conformation 1) |
|
184
|
595
|
8vkoD |
Cryo-em structure of sars-cov-2 xbb.1.5 spike protein in complex with human ace2 |
|
185
|
1114
|
8tylA |
Structural and biochemical rationale for beta variant protein booster vaccine broad cross-neutralization of sars-cov-2 |
|
172
|
1111
|
8tyoA |
Structural and biochemical rationale for beta variant protein booster vaccine broad cross-neutralization of sars-cov-2 |
|
182
|
1120
|
8i9bA |
S-ecd (omicron ba.2.75) in complex with pd of ace2 |
|
153
|
597
|
8i9cD |
S-ecd (omicron bf.7) in complex with pd of ace2 |
